Veradermics Reports Positive Phase 3 Data for Oral Hair Loss Treatment VDPHL01
What happened
Veradermics reported positive phase 3 data for VDPHL01, an oral, extended-release version of minoxidil. The study involved 536 men with mild to moderate hair loss, showing that both once-daily and twice-daily doses outperformed the placebo. Patients taking the once-daily dose gained an average of 28.6 hairs per square centimeter, while the twice-daily dose resulted in 36.4 hairs per square centimeter, compared to 6.6 for the placebo. Dermatologist Pooja Shah commented on the positive results of the oral treatment.
From nypost.com
Why it matters
The drug represents a potential new oral treatment for pattern baldness after nearly 30 years. Veradermics and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.
Veradermics and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.
From nypost.com
Who's involved
- Pooja ShahDermatologist who commented on the positive phase 3 trial results.
- FDARegulatory body overseeing the drug approval process.